Filtering by:
TreatmentPatients with a Late Diagnosis of Metastatic Cancer May Be Overtreated
Nearly 30% of people who died within 1 month of being diagnosed with an incurable cancer got aggressive treatment that may have been ineffective, according to a new American Cancer Society (ACS) study. The study's lead author was Helmneh M. Sineshaw, MD, MPH, a principal scientist in health services at the ACS.
The Truth About Alternative Medical Treatments
Some non-standard therapies can help some people feel better during treatment for cancer or other serious illnesses. But others are money wasters or downright dangerous. Find out what to look for.
2018 in Review: Top 10 Cancer News Stories
In 2018 we published stories about new findings in cancer risk factors, prevention, treatment, and survivorship issues. Our writers and editors have chosen the 10 most significant stories that made headlines on cancer.org this year.
2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
Studies Find Open Surgery Safer For Early Cervical Cancer
Researchers at the University of Texas MD Anderson Cancer Center and colleagues find that women who undergo minimally invasive radical hysterectomy to treat early-stage cervical cancer have worse outcomes than women who undergo abdominal “open” radical hysterectomy.
Study Supports Immunotherapy for Treating Triple-Negative Breast Cancer
A study by an international group of researchers has found for the first time that a combination of immunotherapy and chemotherapy can extend lives of women with triple-negative breast cancer.
New Prostate Cancer Guideline Offers Shortened Radiation Time
Men being treated for early-stage prostate cancer with external beam radiation therapy (EBRT) can safely choose an option that reduces the number of treatment sessions, according to a panel of experts from the American Society for Radiation Oncology, American Society of Clinical Oncology, and American Urological Association.
FDA Approves Azedra (Iobenguane) for Rare Adrenal Tumors
The US Food and Drug Administration has approved the radiotherapy drug Azedra (iobenguane I-131) to treat some adults and adolescents ages 12 and older with rare tumors of the adrenal gland called pheochromocytomas, as well as for similar tumors outside of the adrenals, called paragangliomas.
